The 2nd European Myeloma Network (EMN) was held virtually, on March 3–6, 2021.
Experts in the field came together online to discuss and debate the latest updates in the field.
First results of the 2nd H2H of iBTKs: the ALPINE study. With a 15 months follow up. So different population from ELEVATE RR #iwCLL2021 @PeterHillmen #CLL
Great talk on bispecific antibodies by Adrian Wiestner at the #iwCLL2021 meeting! 👨⚕️💉 Watch interviews with CLL experts here 👉http://ow.ly/vyi850GbSPz👈 @VJHemOnc @iwCLL #CLLsm #LEUsm #Leukemia 3
⭐@ninashah33 of @UofCalifornia gives us all the latest developments on the use of alloCAR-T therapies ⭐ Watch: 👉http://ow.ly/k1V050G7DAQ👈 @SocietyofHemOnc #SOHO2021 #HemOnc #ImmunoOnc #CART #BloodCancerAwarenessMonth #CancelBloodCancer #BCAM
In advance of our 2nd debate at #iwCLL2021 between Peter Dreger and @drjgauthier, which type of cellular therapy do you prefer for your patients with CLL?
Very nice description of a very difficult clinical situation: Richter’s Transformation with CNS involvement. Presented by @YucaiWangMD @WeiDing3 at #iwCLL2021
The iwMyeloma 2021 meeting is a high-level discussion forum for research leaders in the field of myeloma.
By choosing to continue, you are confirming that you are a healthcare professional
Please enter your details if you would like to receive the latest hemonc news and updates
Keep up to date with all the latest news with our monthly newsletter